• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way.乳腺癌的分子分类:从传统、过时的方式到新时代、新方法。
J Breast Health. 2015 Apr 1;11(2):59-66. doi: 10.5152/tjbh.2015.1669. eCollection 2015 Apr.
2
Molecular classification of breast carcinomas with particular emphasis on "basal-like" carcinoma: a critical review.乳腺癌的分子分类,特别强调“基底样”癌:批判性回顾。
J Biophotonics. 2012 Apr;5(4):345-66. doi: 10.1002/jbio.201100097. Epub 2012 Jan 9.
3
Molecular classification of breast cancer: is it time to pack up our microscopes?乳腺癌的分子分类:是时候放下我们的显微镜了吗?
Pathology. 2011 Jan;43(1):1-8. doi: 10.1097/PAT.0b013e328341e0b5.
4
Molecular classifications of breast carcinoma with similar terminology and different definitions: are they the same?具有相似术语但定义不同的乳腺癌分子分类:它们相同吗?
Hum Pathol. 2008 Apr;39(4):506-13. doi: 10.1016/j.humpath.2007.09.005. Epub 2008 Mar 4.
5
Mixture classification model based on clinical markers for breast cancer prognosis.基于临床标志物的乳腺癌预后混合分类模型。
Artif Intell Med. 2010 Feb-Mar;48(2-3):129-37. doi: 10.1016/j.artmed.2009.07.008. Epub 2009 Dec 14.
6
Classifications and prognosis of breast cancer: from morphology to molecular taxonomy.乳腺癌的分类和预后:从形态学到分子分类学。
Breast J. 2010 Sep-Oct;16 Suppl 1:S15-6. doi: 10.1111/j.1524-4741.2010.00995.x.
7
Molecular classification of infiltrating breast cancer: toward personalized therapy.浸润性乳腺癌的分子分类:走向个体化治疗。
Radiographics. 2014 Sep-Oct;34(5):1178-95. doi: 10.1148/rg.345130049.
8
Molecular and morphologic distinctions between infiltrating ductal and lobular carcinoma of the breast.乳腺浸润性导管癌和小叶癌之间的分子及形态学差异。
Breast J. 2007 Mar-Apr;13(2):172-9. doi: 10.1111/j.1524-4741.2007.00393.x.
9
[Hopes and pitfalls of the molecular classification of breast cancer].[乳腺癌分子分类的希望与陷阱]
Cesk Patol. 2015;51(1):26-32.
10
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.预防性卵巢切除术:降低美国上皮性卵巢癌死亡率。一场持续的争论。
Oncologist. 1996;1(5):326-330.

引用本文的文献

1
Targeting EGFR/IGF-IR Functional Crosstalk in 2D and 3D Triple-Negative Breast Cancer Models to Evaluate Tumor Progression.在二维和三维三阴性乳腺癌模型中靶向表皮生长因子受体/胰岛素样生长因子-1受体功能串扰以评估肿瘤进展
Int J Mol Sci. 2025 Sep 5;26(17):8665. doi: 10.3390/ijms26178665.
2
Drug resistance and tumor heterogeneity: cells and ensembles.耐药性与肿瘤异质性:细胞与细胞群体
Biophys Rev. 2025 May 31;17(3):759-779. doi: 10.1007/s12551-025-01320-y. eCollection 2025 Jun.
3
Subtype- and race-specific variations in the immune landscape of breast cancer: therapeutic implications.乳腺癌免疫格局中的亚型和种族特异性差异:治疗意义
NPJ Breast Cancer. 2025 Jul 24;11(1):78. doi: 10.1038/s41523-025-00799-8.
4
Impact of neoadjuvant therapy on cancer stem cell gene expression and miRNA profiles in breast cancer patients: Implications for therapy resistance and survival, a cross-sectional observational study.新辅助治疗对乳腺癌患者癌症干细胞基因表达和微小RNA谱的影响:对治疗抵抗和生存的意义,一项横断面观察性研究
Medicine (Baltimore). 2025 Jun 27;104(26):e43077. doi: 10.1097/MD.0000000000043077.
5
Futility in healthcare among Mexican female patients with breast cancer in advanced stage: The patient perspective.晚期乳腺癌墨西哥女性患者对医疗保健无效性的看法:患者视角
PLoS One. 2025 Jun 23;20(6):e0326332. doi: 10.1371/journal.pone.0326332. eCollection 2025.
6
Combining KPNA2 and FOXM1 Expression as Prognostic Markers and Therapeutic Targets in Hormone Receptor-Positive, HER2-Negative Breast Cancer.联合KPNA2和FOXM1表达作为激素受体阳性、HER2阴性乳腺癌的预后标志物和治疗靶点
Cancers (Basel). 2025 Feb 17;17(4):671. doi: 10.3390/cancers17040671.
7
Selisistat, a SIRT1 inhibitor, enhances paclitaxel activity in luminal and triple-negative breast cancer: in silico, in vitro, and in vivo studies.SIRT1抑制剂西利西他增强了紫杉醇在腔面型和三阴性乳腺癌中的活性:计算机模拟、体外和体内研究。
J Enzyme Inhib Med Chem. 2025 Dec;40(1):2458554. doi: 10.1080/14756366.2025.2458554. Epub 2025 Feb 12.
8
Unveiling the role of SYNGR4 in breast cancer development: a novel target for immunotherapy.揭示SYNGR4在乳腺癌发展中的作用:免疫治疗的新靶点。
Front Oncol. 2025 Jan 20;14:1490073. doi: 10.3389/fonc.2024.1490073. eCollection 2024.
9
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma.通过一种基于创新型cVLP的疫苗靶向前蛋白转化酶枯草溶菌素9(PCSK9),增强了cVLP-人表皮生长因子受体2(HER2)疫苗在HER2阳性乳腺癌临床前模型中的治疗活性。
J Transl Med. 2025 Jan 30;23(1):136. doi: 10.1186/s12967-025-06126-w.
10
Mechanistic insights into pachymic acid's action on triple-negative breast Cancer through TOP2A targeting.通过靶向TOP2A对茯苓酸作用于三阴性乳腺癌的机制性见解。
Sci Rep. 2025 Jan 22;15(1):2856. doi: 10.1038/s41598-025-87286-z.

本文引用的文献

1
Comprehensive molecular portraits of human breast tumours.人类乳腺肿瘤的全面分子特征图谱。
Nature. 2012 Oct 4;490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23.
2
PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer.PAM50 检测和三基因模型用于鉴定乳腺癌的主要且具有临床相关性的分子亚型。
Breast Cancer Res Treat. 2012 Aug;135(1):301-6. doi: 10.1007/s10549-012-2143-0. Epub 2012 Jul 3.
3
A three-gene model to robustly identify breast cancer molecular subtypes.一种稳健识别乳腺癌分子亚型的三基因模型。
J Natl Cancer Inst. 2012 Feb 22;104(4):311-25. doi: 10.1093/jnci/djr545. Epub 2012 Jan 18.
4
Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement.基于微阵列的乳腺癌分子分类的分类发现:观察者间一致性分析。
J Natl Cancer Inst. 2011 Apr 20;103(8):662-73. doi: 10.1093/jnci/djr071. Epub 2011 Mar 18.
5
Global cancer statistics.全球癌症统计数据。
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. doi: 10.3322/caac.20107. Epub 2011 Feb 4.
6
Molecular classification of breast cancer: is it time to pack up our microscopes?乳腺癌的分子分类:是时候放下我们的显微镜了吗?
Pathology. 2011 Jan;43(1):1-8. doi: 10.1097/PAT.0b013e328341e0b5.
7
A major role of p95/611-CTF, a carboxy-terminal fragment of HER2, in the down-modulation of the estrogen receptor in HER2-positive breast cancers.p95/611-CTF,HER2 的羧基末端片段,在 HER2 阳性乳腺癌中雌激素受体下调中的主要作用。
Cancer Res. 2010 Nov 1;70(21):8537-46. doi: 10.1158/0008-5472.CAN-10-1701. Epub 2010 Oct 26.
8
Clinical and biological significance of E-cadherin protein expression in invasive lobular carcinoma of the breast.E-钙黏蛋白在乳腺浸润性小叶癌中的表达的临床和生物学意义。
Am J Surg Pathol. 2010 Oct;34(10):1472-9. doi: 10.1097/PAS.0b013e3181f01916.
9
Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer.乳腺癌中抗人表皮生长因子受体 2 制剂的耐药机制。
Cancer Sci. 2011 Jan;102(1):1-8. doi: 10.1111/j.1349-7006.2010.01711.x. Epub 2010 Sep 6.
10
Breast cancer prognostic classification in the molecular era: the role of histological grade.分子时代的乳腺癌预后分类:组织学分级的作用。
Breast Cancer Res. 2010;12(4):207. doi: 10.1186/bcr2607. Epub 2010 Jul 30.

乳腺癌的分子分类:从传统、过时的方式到新时代、新方法。

Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way.

作者信息

Eliyatkın Nuket, Yalçın Evrim, Zengel Baha, Aktaş Safiye, Vardar Enver

机构信息

Department of Pathology, İzmir Bozyaka Training and Research Hospital, İzmir, Turkey.

Department of Pathology, Erciş State Hospital, Van, Turkey.

出版信息

J Breast Health. 2015 Apr 1;11(2):59-66. doi: 10.5152/tjbh.2015.1669. eCollection 2015 Apr.

DOI:10.5152/tjbh.2015.1669
PMID:28331693
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5351488/
Abstract

Breast carcinoma comprises a group of diseases with specific clinical, histopathologic and molecular properties. Traditional classification use morphology to divide tumors into separate categories with differing behavior and prognosis. However, there are limitations of traditional classification systems, and new molecular methods are expected to improve classification systems. Molecular subtypes of breast carcinomas have been characterized in the last 11 years, and have been studied extensively. Much of the information accumulated in recent years, and molecular taxonomy seems to be still developing and undergoing change. The main question is whether new molecular techniques such as gene expression profiling will be accepted as gold standard in determining breast cancer subtypes, and whether molecular classification is useful in specific subtypes of breast cancer as it is in ductal carcinoma (nonspecific type). In addition, critical review of the literature reveals major problems such as poor definition, lack of reproducibility and lack of quality control in current molecular techniques and classifications. Therefore, current molecular approaches are not yet used in routine clinical practice and treatment guidance since they are immature and can even lead to incorrect assessment.

摘要

乳腺癌是一组具有特定临床、组织病理学和分子特性的疾病。传统分类利用形态学将肿瘤分为具有不同行为和预后的不同类别。然而,传统分类系统存在局限性,新的分子方法有望改进分类系统。乳腺癌的分子亚型在过去11年中已得到表征,并得到了广泛研究。近年来积累了大量信息,分子分类法似乎仍在发展和变化。主要问题是诸如基因表达谱分析等新的分子技术是否会被接受为确定乳腺癌亚型的金标准,以及分子分类在乳腺癌的特定亚型中是否像在导管癌(非特殊类型)中一样有用。此外,对文献的批判性审查揭示了当前分子技术和分类中存在的主要问题,如定义不明确、缺乏可重复性和缺乏质量控制。因此,目前的分子方法尚未用于常规临床实践和治疗指导,因为它们尚不成熟,甚至可能导致错误的评估。